MGMT promoter region methylation has been demonstrated in 7–55% of NSCLC14,22,23 and is an independent predictor of poor prognosis in one study,9 whereas others have not been able to demonstrate a significant association with survival.24 Immunohistochemical expression of MGMT has been studied in a group of 83 stage I–III NSCLC and reduced expression was found in only 25% of cases,6 compared with 77.8% in our study. Here, MGMT is linked to non-small cell lung carcinoma.